scholarly journals Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience

2017 ◽  
Vol 33 (3) ◽  
pp. 221-226 ◽  
Author(s):  
Friederike Eisner ◽  
Diana Hermann ◽  
Khaled Bajaeifer ◽  
Jörg Glatzle ◽  
Alfred Königsrainer ◽  
...  
Keyword(s):  
Gastric Ulcer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clinical Routine ◽  
Ulcer Complications

Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population‐based cohort study

2020 ◽  
Vol 26 (3) ◽  
pp. 474-478 ◽  
Author(s):  
Dah‐Ching Ding ◽  
Fung‐Chang Sung ◽  
Weishan Chen ◽  
Jen‐Hung Wang ◽  
Shinn‐Zong Lin
Keyword(s):  
Breast Cancer ◽  
Gastric Ulcer ◽  
Cohort Study ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Population Based ◽  
Reduce Breast Cancer Risk

scholarly journals Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

2020 ◽  
Vol 33 (2) ◽  
pp. 57-60
Author(s):  
Olesya P. Balitska ◽  
Tamara A. Germanyuk ◽  
Yuliia M. Hryhoruk ◽  
Tatiana I. Ivko ◽  
Yuliia O. Tomashevska ◽  
...  
Keyword(s):  
Duodenal Ulcer ◽  
Gastric Ulcer ◽  
Proton Pump Inhibitor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Inhibitory Effect ◽  
Pharmaceutical Market ◽  
Duodenal Ulcers ◽  
Treatment Regimens

AbstractAim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature.Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis.Methods. Descriptive, statistical, retrospective.Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).

Sign in / Sign up

Export Citation Format

Share Document